Apart from the two "Docs", there is someone else I know who will be very upset if Remestemcel_L is approved for GvHD. Look at the proportion of Incyte's revenue that is attributable to Jakafi (ruxolitinib). The Jakafi revenue ($2.5B) is not wholly attributable to GvHD sales, but a very large part of it is:
Apart from the two "Docs", there is someone else I know who will...
-
- There are more pages in this discussion • 1,398 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.13 |
Change
-0.025(2.17%) |
Mkt cap ! $1.284B | |||
| Open | High | Low | Value | Volume |
| $1.15 | $1.16 | $1.11 | $7.363M | 6.488M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 94863 | $1.13 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.13 | 5000 | 2 |
View Market Depth
| Last trade - 16.10pm 26/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |